Janus Henderson Group PLC lifted its stake in Globus Medical Inc (NYSE:GMED) by 260.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,683,312 shares of the medical device company’s stock after purchasing an additional 1,938,039 shares during the quarter. Janus Henderson Group PLC owned about 3.72% of Globus Medical worth $88,952,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. AHL Partners LLP raised its position in shares of Globus Medical by 5.2% in the 2nd quarter. AHL Partners LLP now owns 418,079 shares of the medical device company’s stock valued at $13,859,000 after purchasing an additional 20,771 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Globus Medical by 26.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 166,090 shares of the medical device company’s stock valued at $5,505,000 after purchasing an additional 34,513 shares during the last quarter. Tudor Investment Corp ET AL raised its position in shares of Globus Medical by 98.3% in the 2nd quarter. Tudor Investment Corp ET AL now owns 17,651 shares of the medical device company’s stock valued at $585,000 after purchasing an additional 8,751 shares during the last quarter. First Allied Advisory Services Inc. raised its position in shares of Globus Medical by 49.2% in the 2nd quarter. First Allied Advisory Services Inc. now owns 12,096 shares of the medical device company’s stock valued at $399,000 after purchasing an additional 3,991 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new position in shares of Globus Medical in the 2nd quarter valued at approximately $341,000. 65.64% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/11/globus-medical-inc-gmed-shares-bought-by-janus-henderson-group-plc.html.

Several brokerages recently commented on GMED. BidaskClub raised shares of Globus Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research lowered shares of Globus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Globus Medical in a research report on Wednesday, August 30th. Canaccord Genuity reissued a “buy” rating and set a $38.00 price target on shares of Globus Medical in a research report on Friday, September 22nd. Finally, BTIG Research began coverage on shares of Globus Medical in a research report on Thursday, September 7th. They set a “buy” rating and a $37.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $30.71.

Globus Medical Inc (NYSE GMED) opened at 29.69 on Wednesday. The firm’s 50-day moving average is $29.93 and its 200-day moving average is $30.90. Globus Medical Inc has a 52-week low of $19.25 and a 52-week high of $34.03. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of 26.75 and a beta of 0.56.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.02. The business had revenue of $152.39 million during the quarter, compared to analyst estimates of $150.94 million. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The company’s revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.29 earnings per share. Analysts predict that Globus Medical Inc will post $1.26 earnings per share for the current year.

In other Globus Medical news, insider A Brett Murphy sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $29.99, for a total value of $449,850.00. Following the completion of the transaction, the insider now directly owns 101,217 shares in the company, valued at $3,035,497.83. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 28.21% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Stock Ratings for Globus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc and related stocks with our FREE daily email newsletter.